A semaglutide molecule contains 31 amino acids assembled in a precise sequence with a fatty-acid side chain anchored at a specific position. Producing this molecule at the scale required for tens of millions of weekly doses requires industrial chemistry that very few companies in the world can perform. The competitive dynamics of the GLP-1 market—the persistence of shortages, the structure of supply contracts, the geography of manufacturing investment—are fundamentally determined by this fact, and yet the public conversation about GLP-1s rarely engages it.
Peptide drugs occupy an awkward middle position in the pharmaceutical industry’s industrial taxonomy. They are too large and too complex to be produced through the well-established pathways of small-molecule chemistry, but too small to be expressed economically in the mammalian cell-culture systems that produce monoclonal antibodies and most other large biologics. Peptides are typically synthesized through solid-phase peptide synthesis, a process developed in the 1960s by Bruce Merrifield that builds peptides one amino acid at a time on a solid resin support. The chemistry is reliable. The yields, however, fall geometrically with peptide length, and a 31-amino-acid peptide like semaglutide produced at clinical scale generates a substantial waste stream of incomplete or improperly assembled molecules that must be purified away.
The capital intensity of peptide manufacturing facilities is, in consequence, considerable. A facility capable of producing semaglutide at the volumes Novo Nordisk requires represents a multi-billion-dollar capital expenditure, with construction timelines of three to five years from groundbreaking to validated production. The pharmaceutical industry’s experience with capacity-constrained markets is that companies under-invest in capacity during the development phase because the demand uncertainty is too great to justify the capital risk, then over-invest after the demand materializes because the lost revenue from constrained supply exceeds the marginal cost of additional capacity. The GLP-1 market followed this pattern with unusual clarity. Both Novo Nordisk and Lilly invested in capacity expansions during the late 2010s that proved inadequate by 2022, and the capital programs they have announced since 2022 represent some of the largest pharmaceutical manufacturing investments in industry history.
Novo Nordisk’s announcement in February 2024 of a $4.1 billion expansion of its Clayton, North Carolina facility, designed specifically to serve US semaglutide demand, was the largest in the company’s history. Lilly’s investments at Concord, North Carolina; Indianapolis; and Research Triangle Park have totaled over $20 billion since 2020, with much of the new capacity dedicated to tirzepatide and pipeline GLP-1 derivatives. These figures are not exceptional in the context of pharmaceutical biologic manufacturing—comparable investments have been made by major monoclonal antibody manufacturers in the 2010s—but their concentration in a single therapeutic class, on this compressed timeline, is genuinely unusual.
The fill-finish bottleneck deserves separate discussion because it is the constraint that most directly shapes patient access in the short term. Fill-finish refers to the final stage of injectable drug manufacturing, in which the bulk drug substance is filled into vials, cartridges, or pre-filled syringes under sterile conditions, inspected, packaged, and released. Fill-finish capacity globally is constrained, and the constraint cannot be relaxed quickly. A new fill-finish line requires not only capital but qualification—a multi-year process of validation, regulatory inspection, and process verification. During the COVID-19 vaccine rollout, fill-finish bottlenecks were the primary determinant of which countries received vaccine when, and the same dynamic has now reshaped the GLP-1 market.
What complicates the fill-finish question for GLP-1s specifically is the proliferation of delivery devices. Semaglutide and tirzepatide are administered through proprietary auto-injectors—Ozempic’s pen, Wegovy’s pen, Zepbound’s pen—each of which requires its own manufacturing line, regulatory approval, and quality oversight. The devices are themselves capacity-constrained, and the device manufacturers have lead times on new line installations that exceed the lead times for the underlying drug substance. A pharmaceutical company that wants to expand GLP-1 production has to coordinate three parallel capacity expansions—drug substance, fill-finish, and device assembly—each with its own constraints, validation requirements, and supplier relationships.
Contract manufacturing organizations have absorbed some of this demand, but the picture is uneven. Catalent, the largest contract development and manufacturing organization with substantial fill-finish capacity, was acquired by Novo Holdings in late 2024 partly to secure manufacturing access for Novo Nordisk’s GLP-1 pipeline. The acquisition removed a substantial fraction of independent fill-finish capacity from the market, with secondary effects on other pharmaceutical companies dependent on Catalent for their own products. Several non-Novo manufacturers reported supply concerns following the acquisition announcement, and the FTC investigated the deal before allowing it to close with limited divestiture conditions.
The geographic concentration of peptide manufacturing has become its own policy concern. The bulk of global semaglutide and tirzepatide production happens in a small number of locations: Novo Nordisk’s facilities in Denmark and the United States, Lilly’s facilities in the US and Europe, and a handful of contract manufacturers. The supply chain for the underlying amino acids and reagents passes through Chinese chemical manufacturers with substantial market share in specific intermediate compounds. The geopolitical exposure of GLP-1 supply, while not currently disrupted, has become a topic of quiet concern at HHS and at the major pharmaceutical companies, with some early efforts to onshore intermediate production.
The economic implications of the manufacturing bottleneck for pricing are easier to describe than to model precisely. In a market where demand exceeds supply, manufacturers have very little reason to lower prices—any patient who would have bought the drug at the higher price is already buying it. The capacity expansions of 2024 and 2025 have begun to bring supply closer to demand, but the demand itself continues to expand as new indications, new patient populations, and new geographies enter the market. Whether prices will fall once supply catches up depends on whether competition from new market entrants—generic semaglutide whenever patents permit, oral GLP-1 formulations that change the manufacturing equation, and entirely novel mechanism-of-action drugs that may displace GLP-1s for specific indications—materializes on a timeline that disciplines the incumbents.
There is a parallel set of considerations about how peptide manufacturing capacity will affect the broader pipeline of peptide-based drugs. The GLP-1 capacity buildup, while focused on specific molecules, has involved general capability expansion in solid-phase peptide synthesis at industrial scale. Other peptide drugs in development—amylin analogs, glucagon analogs, dual and triple agonists, and various peptide-based oncology candidates—will benefit from the manufacturing infrastructure that GLP-1s have justified. Several mid-sized pharmaceutical companies with peptide-based pipelines have announced manufacturing partnerships that effectively share capacity built primarily for GLP-1 demand. The capacity expansion may, in this sense, accelerate the broader peptide drug landscape in ways the original capital decisions did not contemplate.
What the manufacturing bottleneck reveals, when one looks at the GLP-1 market through this lens rather than the pricing lens, is that the structural constraint on broader access is not financial but industrial. Patients in the United States who could afford semaglutide at compounded prices, or insurers who could afford it at deeply discounted negotiated prices, were nevertheless rationed by physical supply during 2023 and 2024. The financial reform proposals that dominate the policy conversation—Medicare negotiation, mandatory pass-through rebates, even most-favored-nation pricing—do not change the production capacity equation. A negotiated price the manufacturer cannot supply is no price at all. The slower and less rhetorically satisfying work of expanding global peptide manufacturing capacity, in fill-finish lines, in API synthesis, in qualified contract manufacturers, is the work that actually determines who gets the drugs. The financial conversation is louder. The industrial conversation is the one that matters.
